Search Results

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings.

Actinium Pharmaceuticals, Inc. announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society being held April 14 – 17, 2024, in Glasgow, Scotland.

Protara is advancing a cell therapy that triggers both adaptive and innate antitumor immune responses, while CG Oncology’s approach makes use of an oncolytic immunotherapy that preferentially targets cancer cells and proliferates inside them, destroying them from the inside.

Sierra Oncology, Inc. today reported its financial and operating results for the first quarter ended March 31, 2022.

ADAMA Ltd. announces the registration of Sierra®, its self-produced Saflufenacil-based herbicide formulation, the first off-patent product based on this active ingredient, in Australia.

Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022.

Sierra Space announced it has developed a pathfinder spaceflight investigation in collaboration with BioServe Space Technologies and other partners to grow hematopoietic stem cells in microgravity to better help patients on Earth undergoing treatment for blood cancer.

Actinium Pharmaceuticals, Inc. announced that three abstracts detailing results from the completed Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia have been accepted for presentation at the 65th Annual American Society of Hematology Annual Meeting & Exposition being held in San Diego on December 9-12, 2023.

Sierra Oncology, Inc. today reported its financial and operating results for the fourth quarter and fiscal year ended December 31, 2021.